Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests ...

In today’s fast-paced, innovation-fueled biopharma landscape, the traditional model of C-suite leadership is being turned on ...

One of the concerns people have when they hear FDA is using AI in the drug approval process is that many people don't have a ...

The Medipost CEO discusses developing treatments for knee osteoarthritis and other conditions.

The White House’s plans to make significant cuts to funding from NIH is expected to have significant impact on the pharma industry for years to come. Justin Kozak, an executive VP at Founder Shield, ...